Human C1-esterase inhibitor CSL Behring লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

human c1-esterase inhibitor csl behring

csl behring gmbh - Žmogaus c1-esterazės inhibitorius - milteliai ir tirpiklis injekciniam tirpalui - 2000 tv - c1-inhibitor, plasma derived

Human C1-esterase inhibitor CSL Behring লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

human c1-esterase inhibitor csl behring

csl behring gmbh - Žmogaus c1-esterazės inhibitorius - milteliai ir tirpiklis injekciniam tirpalui - 3000 tv - c1-inhibitor, plasma derived

Haemate লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

haemate

csl behring gmbh - Žmogaus viii koaguliacijos faktorius /Žmogaus willebrando faktorius - milteliai ir tirpiklis injekciniam ar infuziniam tirpalui - 250 tv/600 tv - von willebrand factor and coagulation factor viii in combination

Haemate লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

haemate

csl behring gmbh - Žmogaus viii koaguliacijos faktorius /Žmogaus willebrando faktorius - milteliai ir tirpiklis injekciniam ar infuziniam tirpalui - 500 tv/1200 tv - von willebrand factor and coagulation factor viii in combination

Haemate লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

haemate

csl behring gmbh - Žmogaus viii koaguliacijos faktorius /Žmogaus willebrando faktorius - milteliai ir tirpiklis injekciniam ar infuziniam tirpalui - 1000 tv/2400 tv - von willebrand factor and coagulation factor viii in combination

Praxbind ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

praxbind

boehringer ingelheim international gmbh - idarukizumabas - hemoragija - visi kiti gydomieji produktai - praxbind yra specialus atstatymas agentas dabigatran ir yra nurodyta suaugusių pacientų, gydytų pradaxa (dabigatran etexilate), kai reikia greitai atstatymas savo antikoaguliantų poveikis yra būtinas:dėl skubios operacijos/skubiai procedūras;pavojų gyvybei, arba nekontroliuojamas kraujavimas.

Udenyca ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

udenyca

era consulting gmbh - pegfilgrastimas - neutropenija - immunostimulants, , kolonijas stimuliuojantis faktorius - neutropenija ir febrili neutropenija sergantiems suaugusiesiems pasireiškimo trukmės mažinimas pacientams, kurių onkologinės ligos (išskyrus lėtinį mieloidinę leukemiją ir mielodisplazinį sindromą).

Giapreza ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

giapreza

paion deutschland gmbh - angiotenzino ii acetatas - hypotension; shock - renino ir angiotenzino sistemos veikiantys vaistai - giapreza fluorouracilu ir folino ugniai atsparių hipotenzija suaugusiems su septinių ar kitus paskirstymo šoko, kurie lieka hypotensive nepaisant tinkamo tūrio restitucijos taikymo ir katecholaminų ir kitų galimų vasopressor terapija.

Comirnaty ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Cymvigo লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

cymvigo

biotest pharma gmbh - Žmogaus citomegalo viruso imunoglobulinas - infuzinis tirpalas - 100 v/ml - cytomegalovirus immunoglobulin